PUBLISHER: KBV Research | PRODUCT CODE: 1093087
PUBLISHER: KBV Research | PRODUCT CODE: 1093087
LAMEA Ulcerative Colitis Market Size, Share & Industry Trends Analysis Report By Molecule Type (Small Molecules and Biologics), By Disease Type, By Route of Administration, By Country and Growth Forecast, 2022 - 2028
The Latin America, Middle East and Africa Ulcerative Colitis Market would witness market growth of 8.1% CAGR during the forecast period (2022-2028).
Ulcerative colitis is an inflammatory bowel disease (IBD) that produces inflammation and ulcers (sores) in the digestive tract, according to the report's description. The innermost lining of the large intestine (colon) and rectum are affected by ulcerative colitis. Symptoms usually appear gradually rather than abruptly. The focus on diagnosis and therapy to minimize and control the signs and symptoms of ulcerative colitis is driving up the demand for ulcerative colitis drugs. There is currently no permanent cure for Ulcerative Colitis, and the specific origin of the condition's onset is unknown. Several types of medications may be beneficial in the treatment of the symptoms. The sort of medication or therapy provided to a patient is mostly determined by the disease's aetiology and severity. The treatments given to people with the illness are mainly aimed at lowering swelling and inflammation, as well as maintaining a healthy diet, which helps to alleviate many of the symptoms.
Ulcerative colitis is said to be uncommon among black people in Sub-Saharan Africa. The majority of patients (72 percent) arrived with severe symptoms and substantial colonic involvement, according to this group of the first 46 patients treated at Baragwanath Hospital in Soweto. There's a dichotomy here: there are a lot of diseases, but there aren't many consequences that necessitate surgery. This is most likely owing to medical treatment, especially corticosteroid medication, altering the disease's natural history.
Moreover, an increase in inflammatory bowel disease risk factors such as smoking, drinking, sedentary lifestyle, and non-nutritious food consumption may increase the occurrence of inflammatory bowel disease, which would help the regional market to expand further. Furthermore, the market is expected to develop due to comparatively permissive drug regulatory rules and increased government initiatives for healthcare reform. Some of the major trends of the regional market are increased healthcare expenditure and growing standards of living in the region. Therefore, these factors are estimated to propel the growth of the regional Ulcerative Colitis Market over the forecast period.
The Brazil market dominated the LAMEA Ulcerative Colitis Market by Country 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $134.5 million by 2028. The Argentina market is estimated to grow at a CAGR of 8.7% during (2022 - 2028). Additionally, The UAE market would witness a CAGR of 7.8% during (2022 - 2028).
Based on Molecule Type, the market is segmented into Small Molecules and Biologics. Based on Disease Type, the market is segmented into Mild, Moderate, and Severe. Based on Route of Administration, the market is segmented into Oral and Injectables. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Ajinomoto Co., Inc., AstraZeneca PLC, GlaxoSmithKline PLC, Johnson & Johnson, Merck & Co., Inc., Pfizer, Inc., Sanofi S.A., InDex Pharmaceuticals Holding AB, and Eli Lilly And Company.
Scope of the Study
Market Segments covered in the Report:
By Molecule Type
- Small Molecules
- Biologics
By Disease Type
- Mild
- Moderate
- Severe
By Route of Administration
- Oral
- Injectables
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled
- Abbott Laboratories
- Ajinomoto Co., Inc.
- AstraZeneca PLC
- GlaxoSmithKline PLC
- Johnson & Johnson
- Merck & Co., Inc.
- Pfizer, Inc.
- Sanofi S.A.
- InDex Pharmaceuticals Holding AB
- Eli Lilly And Company
Unique Offerings from KBV Research
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
- 1.1 Market Definition
- 1.2 Objectives
- 1.3 Market Scope
- 1.4 Segmentation
- 1.4.1 LAMEA Ulcerative Colitis Market, by Molecule Type
- 1.4.2 LAMEA Ulcerative Colitis Market, by Disease Type
- 1.4.3 LAMEA Ulcerative Colitis Market, by Route of Administration
- 1.4.4 LAMEA Ulcerative Colitis Market, by Country
- 1.5 Methodology for the research
Chapter 2. Market Overview
- 2.1 Introduction
- 2.1.1 Overview
- 2.1.1.1 Market Composition and Scenario
- 2.1.1 Overview
- 2.2 Key Factors Impacting the Market
- 2.2.1 Market Drivers
- 2.2.2 Market Restraints
Chapter 3. Strategies deployed in Ulcerative Colitis Market
Chapter 4. LAMEA Ulcerative Colitis Market by Molecule Type
- 4.1 LAMEA Small Molecules Market by Country
- 4.2 LAMEA Biologics Market by Country
Chapter 5. LAMEA Ulcerative Colitis Market by Disease Type
- 5.1 LAMEA Mild Market by Country
- 5.2 LAMEA Moderate Market by Country
- 5.3 LAMEA Severe Market by Country
Chapter 6. LAMEA Ulcerative Colitis Market by Route of Administration
- 6.1 LAMEA Oral Market by Country
- 6.2 LAMEA Injectables Market by Country
Chapter 7. LAMEA Ulcerative Colitis Market by Country
- 7.1 Brazil Ulcerative Colitis Market
- 7.1.1 Brazil Ulcerative Colitis Market by Molecule Type
- 7.1.2 Brazil Ulcerative Colitis Market by Disease Type
- 7.1.3 Brazil Ulcerative Colitis Market by Route of Administration
- 7.2 Argentina Ulcerative Colitis Market
- 7.2.1 Argentina Ulcerative Colitis Market by Molecule Type
- 7.2.2 Argentina Ulcerative Colitis Market by Disease Type
- 7.2.3 Argentina Ulcerative Colitis Market by Route of Administration
- 7.3 UAE Ulcerative Colitis Market
- 7.3.1 UAE Ulcerative Colitis Market by Molecule Type
- 7.3.2 UAE Ulcerative Colitis Market by Disease Type
- 7.3.3 UAE Ulcerative Colitis Market by Route of Administration
- 7.4 Saudi Arabia Ulcerative Colitis Market
- 7.4.1 Saudi Arabia Ulcerative Colitis Market by Molecule Type
- 7.4.2 Saudi Arabia Ulcerative Colitis Market by Disease Type
- 7.4.3 Saudi Arabia Ulcerative Colitis Market by Route of Administration
- 7.5 South Africa Ulcerative Colitis Market
- 7.5.1 South Africa Ulcerative Colitis Market by Molecule Type
- 7.5.2 South Africa Ulcerative Colitis Market by Disease Type
- 7.5.3 South Africa Ulcerative Colitis Market by Route of Administration
- 7.6 Nigeria Ulcerative Colitis Market
- 7.6.1 Nigeria Ulcerative Colitis Market by Molecule Type
- 7.6.2 Nigeria Ulcerative Colitis Market by Disease Type
- 7.6.3 Nigeria Ulcerative Colitis Market by Route of Administration
- 7.7 Rest of LAMEA Ulcerative Colitis Market
- 7.7.1 Rest of LAMEA Ulcerative Colitis Market by Molecule Type
- 7.7.2 Rest of LAMEA Ulcerative Colitis Market by Disease Type
- 7.7.3 Rest of LAMEA Ulcerative Colitis Market by Route of Administration
Chapter 8. Company Profiles
- 8.1 Abbott Laboratories
- 8.1.1 Company Overview
- 8.1.2 Financial Analysis
- 8.1.3 Segmental and Regional Analysis
- 8.1.4 Research & Development Expense
- 8.2 Ajinomoto Co., Inc.
- 8.2.1 Company Overview
- 8.2.2 Financial Analysis
- 8.2.3 Segmental & Regional Analysis
- 8.2.4 Research & Development Expenses
- 8.3 AstraZeneca PLC
- 8.3.1 Company Overview
- 8.3.2 Financial Analysis
- 8.3.3 Regional Analysis
- 8.3.4 Research & Development Expenses
- 8.4 GlaxoSmithKline PLC
- 8.4.1 Company Overview
- 8.4.2 Financial Analysis
- 8.4.3 Segmental and Regional Analysis
- 8.4.4 Research & Development Expense
- 8.5 Johnson & Johnson
- 8.5.1 Company Overview
- 8.5.2 Financial Analysis
- 8.5.3 Segmental &Regional Analysis
- 8.5.4 Research & Development Expenses
- 8.6 Merck & Co., Inc.
- 8.6.1 Company Overview
- 8.6.2 Financial Analysis
- 8.6.3 Segmental and Regional Analysis
- 8.6.4 Research & Development Expenses
- 8.6.5 Recent strategies and developments:
- 8.6.5.1 Acquisition and Mergers:
- 8.7 Pfizer, Inc.
- 8.7.1 Company Overview
- 8.7.2 Financial Analysis
- 8.7.3 Regional & Segmental Analysis
- 8.7.4 Research & Development Expense
- 8.7.5 Recent strategies and developments:
- 8.7.5.1 Acquisition and Mergers:
- 8.7.5.2 Approvals and Trials:
- 8.8 Sanofi S.A.
- 8.8.1 Company Overview
- 8.8.2 Financial Analysis
- 8.8.3 Segmental and Regional Analysis
- 8.8.4 Research & Development Expense
- 8.9 InDex Pharmaceuticals Holding AB
- 8.9.1 Company Overview
- 8.9.2 Financial Analysis
- 8.9.3 Recent strategies and developments:
- 8.9.3.1 Partnerships, Collaborations, and Agreements:
- 8.10. Eli Lilly And Company
- 8.10.1 Company Overview
- 8.10.2 Financial Analysis
- 8.10.3 Segmental and Regional Analysis
- 8.10.4 Research & Development Expenses
LIST OF TABLES
- TABLE 1 LAMEA Ulcerative Colitis Market, 2018 - 2021, USD Million
- TABLE 2 LAMEA Ulcerative Colitis Market, 2022 - 2028, USD Million
- TABLE 3 LAMEA Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
- TABLE 4 LAMEA Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
- TABLE 5 LAMEA Small Molecules Market by Country, 2018 - 2021, USD Million
- TABLE 6 LAMEA Small Molecules Market by Country, 2022 - 2028, USD Million
- TABLE 7 LAMEA Biologics Market by Country, 2018 - 2021, USD Million
- TABLE 8 LAMEA Biologics Market by Country, 2022 - 2028, USD Million
- TABLE 9 LAMEA Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
- TABLE 10 LAMEA Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
- TABLE 11 LAMEA Mild Market by Country, 2018 - 2021, USD Million
- TABLE 12 LAMEA Mild Market by Country, 2022 - 2028, USD Million
- TABLE 13 LAMEA Moderate Market by Country, 2018 - 2021, USD Million
- TABLE 14 LAMEA Moderate Market by Country, 2022 - 2028, USD Million
- TABLE 15 LAMEA Severe Market by Country, 2018 - 2021, USD Million
- TABLE 16 LAMEA Severe Market by Country, 2022 - 2028, USD Million
- TABLE 17 LAMEA Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
- TABLE 18 LAMEA Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
- TABLE 19 LAMEA Oral Market by Country, 2018 - 2021, USD Million
- TABLE 20 LAMEA Oral Market by Country, 2022 - 2028, USD Million
- TABLE 21 LAMEA Injectables Market by Country, 2018 - 2021, USD Million
- TABLE 22 LAMEA Injectables Market by Country, 2022 - 2028, USD Million
- TABLE 23 LAMEA Ulcerative Colitis Market by Country, 2018 - 2021, USD Million
- TABLE 24 LAMEA Ulcerative Colitis Market by Country, 2022 - 2028, USD Million
- TABLE 25 Brazil Ulcerative Colitis Market, 2018 - 2021, USD Million
- TABLE 26 Brazil Ulcerative Colitis Market, 2022 - 2028, USD Million
- TABLE 27 Brazil Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
- TABLE 28 Brazil Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
- TABLE 29 Brazil Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
- TABLE 30 Brazil Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
- TABLE 31 Brazil Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
- TABLE 32 Brazil Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
- TABLE 33 Argentina Ulcerative Colitis Market, 2018 - 2021, USD Million
- TABLE 34 Argentina Ulcerative Colitis Market, 2022 - 2028, USD Million
- TABLE 35 Argentina Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
- TABLE 36 Argentina Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
- TABLE 37 Argentina Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
- TABLE 38 Argentina Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
- TABLE 39 Argentina Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
- TABLE 40 Argentina Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
- TABLE 41 UAE Ulcerative Colitis Market, 2018 - 2021, USD Million
- TABLE 42 UAE Ulcerative Colitis Market, 2022 - 2028, USD Million
- TABLE 43 UAE Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
- TABLE 44 UAE Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
- TABLE 45 UAE Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
- TABLE 46 UAE Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
- TABLE 47 UAE Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
- TABLE 48 UAE Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
- TABLE 49 Saudi Arabia Ulcerative Colitis Market, 2018 - 2021, USD Million
- TABLE 50 Saudi Arabia Ulcerative Colitis Market, 2022 - 2028, USD Million
- TABLE 51 Saudi Arabia Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
- TABLE 52 Saudi Arabia Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
- TABLE 53 Saudi Arabia Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
- TABLE 54 Saudi Arabia Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
- TABLE 55 Saudi Arabia Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
- TABLE 56 Saudi Arabia Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
- TABLE 57 South Africa Ulcerative Colitis Market, 2018 - 2021, USD Million
- TABLE 58 South Africa Ulcerative Colitis Market, 2022 - 2028, USD Million
- TABLE 59 South Africa Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
- TABLE 60 South Africa Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
- TABLE 61 South Africa Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
- TABLE 62 South Africa Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
- TABLE 63 South Africa Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
- TABLE 64 South Africa Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
- TABLE 65 Nigeria Ulcerative Colitis Market, 2018 - 2021, USD Million
- TABLE 66 Nigeria Ulcerative Colitis Market, 2022 - 2028, USD Million
- TABLE 67 Nigeria Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
- TABLE 68 Nigeria Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
- TABLE 69 Nigeria Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
- TABLE 70 Nigeria Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
- TABLE 71 Nigeria Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
- TABLE 72 Nigeria Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
- TABLE 73 Rest of LAMEA Ulcerative Colitis Market, 2018 - 2021, USD Million
- TABLE 74 Rest of LAMEA Ulcerative Colitis Market, 2022 - 2028, USD Million
- TABLE 75 Rest of LAMEA Ulcerative Colitis Market by Molecule Type, 2018 - 2021, USD Million
- TABLE 76 Rest of LAMEA Ulcerative Colitis Market by Molecule Type, 2022 - 2028, USD Million
- TABLE 77 Rest of LAMEA Ulcerative Colitis Market by Disease Type, 2018 - 2021, USD Million
- TABLE 78 Rest of LAMEA Ulcerative Colitis Market by Disease Type, 2022 - 2028, USD Million
- TABLE 79 Rest of LAMEA Ulcerative Colitis Market by Route of Administration, 2018 - 2021, USD Million
- TABLE 80 Rest of LAMEA Ulcerative Colitis Market by Route of Administration, 2022 - 2028, USD Million
- TABLE 81 Key Information - Abbott Laboratories
- TABLE 82 Key information - Ajinomoto Co., Inc.
- TABLE 83 KEY INFORMATION - ASTRAZENECA PLC
- TABLE 84 Key Information - GlaxoSmithKline PLC
- TABLE 85 Key information - Johnson & Johnson
- TABLE 86 KEY INFORMATION - MERCK & CO., INC.
- TABLE 87 Key Information - Pfizer, Inc.
- TABLE 88 Key Information - Sanofi S.A.
- TABLE 89 Key Information - InDex Pharmaceuticals Holding AB
- TABLE 90 Key Information - Eli Lilly And Company
List of Figures
- FIG 1 Methodology for the research
